Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Evaxion A (EVAX) EPS (Weighted Average and Diluted) (2021 - 2023)

Evaxion A posted quarterly EPS (Weighted Average and Diluted) of -$12354.3 for Q2 2023, down 16.6% year-on-year from -$14813.2 in Q2 2022, and down 16.6% on a QoQ basis from -$10595.6 in Q2 2022.

Evaxion A (EVAX) has 3 years of EPS (Weighted Average and Diluted) data on file, last reported at -$12354.3 in Q2 2023.

  • For the quarter ending Q2 2023, EPS (Weighted Average and Diluted) fell 16.6% year-over-year to -$12354.3; the trailing twelve-month figure through Jun 2023 stood at -$12354.3 (down 16.6% YoY), and the FY2023 full-year result was -$0.81, up 17.35% from the prior year.
  • EPS (Weighted Average and Diluted) for Q2 2023 stood at -$12354.3, down from -$10595.6 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$10595.6 in Q2 2022 and bottomed at -$23164.0 in Q1 2022.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$12354.3 (2023), against an average of -$15093.4.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 8.32% in 2022, while the deepest fall reached 30.17% in 2022.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$11557.6 in 2021, then rose by 8.32% to -$10595.6 in 2022, then decreased by 16.6% to -$12354.3 in 2023.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$12354.3 (Q2 2023), -$10595.6 (Q2 2022), and -$23164.0 (Q1 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Revolution Medicines 32.39 Bn 32.39 Bn - -2.29

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 -12,354.35
Jun 30, 2022 -10,595.56
Mar 31, 2022 -23,164.00
Jun 30, 2021 -11,557.63
Mar 31, 2021 -17,795.65